See ((MEK inhibitors))




Mitogen-activated protein kinase 1, also known as MEK1 (MAP2K1)



It is a protein kinase down stream from RAS  and RAF in the signaling cascade that plays in important role in cellular proliferation and differentiation.



MAP2K1 mutations are rare and represent approximately 1-2% of patients with colorectal cancer.



MAP2K1  aberrations was contributed to carcinogenesis.



MAP2K1 in non-small cell lung cancer are associated with the worse prognosis.



MAP2K1 mutations may respond to MEK inhibitors as seen in histiocytic sarcoma, serous ovarian cancer and Langerhans cell histiocytosis.


Leave a Reply

Your email address will not be published. Required fields are marked *